U.S. Attorney General Todd Blanche signed an order this week immediately rescheduling state-licensed medical marijuana from Schedule I to Schedule III under the Controlled Substances Act - a shift that carries real financial consequences for a subset of Colorado operators, while leaving the state's larger adult-use market in a more complicated regulatory position than before. The order also moves FDA-approved cannabis products into Schedule III. Industry attorneys and operators welcomed the acknowledgment of medical value, but the immediate reaction was less celebration than a collective attempt to figure out what, exactly, just changed.
The 280E Question - And Who Actually Benefits
The most concrete near-term effect of rescheduling concerns Section 280E of the Internal Revenue Code. That provision bars businesses trafficking in Schedule I or Schedule II substances from deducting ordinary business expenses - payroll, rent, utilities, insurance - against federal taxable income. For cannabis operators, that prohibition has produced effective tax rates estimated at 70% to 80%, roughly double what comparable licensed businesses in other sectors pay, according to Colorado Leads, a trade group representing the state's cannabis industry.
Rescheduling medical marijuana to Schedule III removes that 280E barrier for operators holding medical licenses. That's not a trivial number, but here's the catch: it is a minority of Colorado's licensed market. As of January, the state's Marijuana Enforcement Division counted 281 licensed medical dispensaries against 687 recreational stores, and 207 licensed medical cultivations against 478 recreational. The businesses that stand to benefit most directly - those operating exclusively under medical licenses - represent less than a third of active retail dispensary locations in Colorado.
For multi-license operators, the picture gets more complicated immediately. Companies holding both medical and recreational licenses, a common structure among vertically integrated businesses, are left with a bifurcated tax situation that no one has fully mapped yet. As Ryan Hunter, chief revenue officer at cannabis manufacturer Spherex - which holds both license types - put it plainly: "Some brilliant accountant is going to have to tell us how this all goes." That's not a dismissal. That's a genuine operational problem that will need answers before the next tax filing cycle.
A Plant Divided Against Itself
The regulatory architecture this order creates is, to put it plainly, strange. Medical cannabis in Colorado is now a Schedule III substance federally. Adult-use cannabis - often produced in the same facility, from the same cultivar, by the same licensed cultivator - remains Schedule I. Hemp, also a cannabis plant, sits outside the Controlled Substances Act entirely, having been removed from the drug schedule in 2018 and reclassified as an agricultural commodity. One plant. Three federal treatments. None of them derived from a consistent scientific or policy logic.
Rachel Gillette, who leads the cannabis and psychedelics practice at Holland & Hart, made the point directly: the criteria embedded in the Controlled Substances Act for placing a substance in a particular schedule don't easily accommodate splitting one substance across two categories based on end-use classification. If marijuana has accepted medical applications - and the Attorney General's order says it does - that finding arguably undermines the entire legal basis for keeping the same plant at Schedule I in a different commercial context.
Chuck Smith, CEO of Colorado Leads, noted that businesses, regulators, and consumers will need federal agency clarity on how the medical and adult-use segments will be treated going forward. That clarity is not yet available.
What Operators Should Watch - And What May Come Next
The DEA is reportedly expected to take up broader marijuana rescheduling discussions in June. That timeline matters enormously for how Colorado's licensed operators - particularly those holding recreational-only licenses - respond to this week's order. Sam Kamin, a law professor at the University of Denver with expertise in cannabis regulation, framed the dilemma directly: if the current bifurcated structure holds for years rather than months, businesses will have strong financial incentive to convert to or emphasize medical operations, push consumers toward obtaining medical marijuana cards, and restructure their license holdings where possible.
That's not a hypothetical. A sustained 280E tax burden on the adult-use side, while medical competitors operate at a lower effective rate, creates real competitive distortion within a state market. Dispensary operators, wholesale suppliers, and licensed cultivators selling primarily into adult-use channels would face structurally higher costs relative to medical-licensed competitors - affecting pricing, margins, and inventory strategy across the supply chain.
There are also unresolved compliance questions at the edges of the new framework. Gillette raised one pointed example: Colorado permits adults to grow cannabis plants at home without a state license. If a homegrower shares product with another person, federal scheduling status determines whether that exchange constitutes trafficking in a Schedule I or Schedule III substance - or whether it crosses any federal threshold at all. No guidance exists yet on questions like that one.
Governor Jared Polis called the order a step in the right direction and pointed to the need for full descheduling to close the gap between federal law and the regulatory reality in states that have built functioning licensed markets. Brian Vicente, a partner at Vicente LLP and a longtime figure in Colorado cannabis law, described the move as incremental progress toward descheduling, and suggested the federal acknowledgment of state medical programs creates a logical foundation for subsequent action on adult-use.
That optimism may be warranted. It also may be premature. The Biden administration's Department of Health and Human Services recommended rescheduling in 2024; the DEA's administrative hearing process stalled, and nothing moved. The signed order this week represents more direct executive action, but the gap between a signed order and a settled regulatory framework - with clear guidance for licensed operators, state agencies, and compliance professionals - remains wide. For Colorado's cannabis businesses, the most honest posture right now is to watch the DEA's next moves carefully and hold off on any structural decisions until the broader rescheduling question is resolved or definitively tabled.
